Cornish, Rosie
Staff, Anne Cathrine
Boyd, Andy
Lawlor, Debbie A.
Tretli, Steinar
Bradwin, Gary
McElrath, Thomas F.
Hyer, Marianne
Hoover, Robert N.
Troisi, Rebecca http://orcid.org/0000-0003-3520-2916
Funding for this research was provided by:
UK Medical Research Council and Wellcome (102215/2/13/2)
Wellcome Trust (WT086118/Z/08/Z)
UK Medical Research Council (MC_UU_1201/5)
National Institute for Health Research (NF-SI-0166-10196)
NIH/NIEHS (N01-ES-75558)
NIH/NINDS (1 UO1 NS 047537- 01, 2 UO1 NS 047537-06A1)
Article History
Received: 18 May 2018
Accepted: 22 November 2018
First Online: 1 December 2018
Compliance with ethical standards
:
: DAL has received support from Roche Diagnostics, Medtronic, UK, EU, and US government funding bodies and UK charities for research unrelated to that presented in this paper. All other authors declare no conflict of interest regarding support for the work under consideration, or for other projects, either financial or in kind from any third party, company or organisation whose finances or reputation may be affected by the publication of the work; any recent, existing or planned employment relationship or consultancy (whether paid or unpaid) any of the authors has with an organisation whose finances or reputation may be affected by the publication of the work; or any direct financial interest any of the authors or their spouses, parents or children has (personal shareholdings, consultancies, patents or patent applications) whose value could be affected by the publication.
: The current analysis makes secondary use of pre-existing data from ALSPAC and MoBa participants who provided written informed consent.
: Ethical approval in ALSPAC was obtained from the ALSPAC Ethics and Law Committee and NHS Research Ethics Committees. Access and use of the linked ALSPAC cancer registry information was restricted to AB and RC who are ONS Accredited Researchers operating within the ONS ‘Safe Research’ framework. MoBa has a license from the Norwegian Data Inspectorate (01-4325) and approval from the Regional Committee for Medical Research Ethics (REK), Southern Norway (S-97045, S-95113). The angiogenic factor study received approval from REK, South-Eastern Norway (S-08541a) and a license from the Norwegian Data Inspectorate (08/01126-4). At the U.S. National Cancer Institute, the project was reviewed by the Office of Human Subjects Research and exempted from institutional review board approval on the basis that the analysis was performed in the U.K. using de-identified data.